Severe asymptomatic hypertension: Ending the urgency of “hypertensive urgency”

Abstract

Severe asymptomatic hypertension (historically termed “hypertensive urgency”) is common in hospital settings and is frequently overtreated. In the absence of acute target organ damage, aggressive short-term blood pressure reduction or parenteral therapy is not recommended. Many patients experience spontaneous decline in blood pressure with rest. In fact, observational studies in non-cardiac inpatients link antihypertensive intensification to increased risk of hypoperfusion to the vital organs. We present a real case illustrating harm from rapid multi-drug stacking and then review a practical approach to management. In line with the latest AHA/ACC 2025 Hypertension Guidelines, we urge all medical practitioners to retire the emotive label of “hypertensive urgency” and adopt “severe asymptomatic hypertension” which better reflects the evidence.

Introduction

Severe asymptomatic hypertension (formally termed “hypertensive urgency”) is defined as markedly elevated BP, typically systolic >180 mmHg and/or diastolic >120 mmHg, without evidence of acute target organ damage. ¹ Although common, its short-term risk of major adverse cardiovascular events (MACE) is low. In a large Cleveland Clinic retrospective cohort, MACE rates at 7 days, 8–30 days and 6 months among patients sent home with severe asymptomatic hypertension were below 1% and did not differ significantly from those referred to the hospital. ² Instead of conferring benefit, intensifying antihypertensive treatment in non-cardiac hospitalised patients with severe hypertension is associated with increased risks of adverse outcomes such as acute kidney injury and myocardial injury. ³ Despite this, the condition often triggers reflexive pharmacological intervention, driven more by terminology “urgency” and clinician anxiety than by evidence.

Case report

An 82-year-old man with type 2 diabetes mellitus and hypertension was admitted with 2 months history of functional decline, postural dizziness and poor appetite. Early in his stay, he had significant postural hypotension and low-normal seated blood pressure (BP), so losartan and isosorbide mononitrate were withheld. About a week later, his BP increased to 215/78 mmHg. As he was asymptomatic, a diagnosis of hypertensive urgency was made. Over the course of 5 hours of “persistently elevated BP”, sequential antihypertensives were prescribed by the on-call doctor: amlodipine 5 mg, then 10 mg, atenolol 50 mg and nifedipine LA 30 mg. He subsequently became profoundly hypotensive, requiring vasopressor support in a high-dependency unit and continuous renal replacement therapy for acute kidney injury.

Discussion

This case illustrates the harm of rapid antihypertensive intensification in severe asymptomatic hypertension, particularly when multiple long-acting agents with delayed onset are administered in quick succession.

When alerted to a patient with severe hypertension, the following steps should be taken:

(1) Confirm BP measurement accuracy

(i) Appropriate cuff size should be used. Using a regular cuff on patients who require a large or extra-large cuff can substantially inflate systolic BP measurements by about 4.8 mm Hg and 19.5 mm Hg, respectively. ⁴

(ii) BP should be measured with the patient seated, back supported, legs uncrossed, and the arm supported at heart level. At heart level, systolic blood pressure (SBP) in the supine position is approximately 7.9–8.2 mm Hg higher than seated. ⁵ In hypertensive patients, crossing the legs during measurement increases SBP by about 8.1–10.5 mm Hg and DBP by about 4.0–4.5 mm Hg. ⁶ Compared with a desk-supported arm, lap-supported hands and an unsupported arm at the side produce statistically higher readings: lap (SBP +3.9 mm Hg, DBP +4.0 mm Hg) and side (SBP +6.5 mm Hg, DBP +4.4 mm Hg). ⁷

(iii) Sufficient rest should be allowed before measurements. An observational study found that most elevated SBP declined by at least 20 mmHg at the next measurement; in selected cases, repeating the measurement 4 hours later may substitute for immediate pharmacological treatment. ³

(2) Assess for evidence of target-organ damage

A clinical assessment should be performed to rule out hypertensive emergency, including acute heart failure, aortic dissection, hypertensive encephalopathy, intracranial haemorrhage, acute ischaemic stroke, acute kidney injury, phaeochromocytoma crisis, and severe pre-eclampsia/eclampsia. Hypertensive emergency is managed according to guideline-directed therapy. ¹

If the assessment is unremarkable, the patient should be classified as having severe asymptomatic hypertension and attention should turn to addressing its contributors.

(3) Identify and address contributors

(i) Pain and distress are common causes of transient BP elevation. In patients with intact cognition, targeted history often reveals the source, whereas in minimally communicative patients, broad differentials include acute coronary syndrome, occult fractures, severe constipation and acute urinary retention. The appropriate response is to address pain with analgesia, treat constipation with adequate aperients, or insert a urinary catheter for urinary retention.

(ii) Anxiety and the white-coat effect are also common contributors. Approximately 10% of the general population has white-coat hypertension, with higher prevalence in older adults. ⁸ Simple measures such as seating the patient in a quiet and comfortable room can lower BP by at least 20/10 mmHg in about one-third of adults with severe asymptomatic hypertension. ⁹ Reassurance, counselling and anxiolytics can be helpful.

(iii) Sleep deprivation is common among inpatients due to noisy environments, lighting and medical interruptions. In hypertensive patients, insufficient sleep increases sympathetic activity, leading to hypertension and tachycardia. ¹⁰

(iv) Iatrogenic hypertension should be addressed. Particular attention should be paid to nonsteroidal anti-inflammatory drugs, high-dose corticosteroids, erythropoietin, cyclosporine, midodrine, and fludrocortisone. Their indications should always be reviewed.

(v) Autonomic dysfunction should be considered in patients with poorly controlled diabetes mellitus, Parkinsonism, previous carotid endarterectomy or prior neck radiotherapy. These patients may have supine hypertension with postural hypotension. Simple strategies such as elevating the head of the bed or sitting the patient up can reduce BP, while intensifying antihypertensives can worsen orthostatic symptoms once the patient mobilises.

(vi) Omitted chronic antihypertensives should be restarted promptly if not contraindicated. Adherence to antihypertensives should be reinforced.

(4) Optimise antihypertensive therapy

If the patient is ready for discharge, optimisation of antihypertensives should be pursued in the outpatient setting rather than through rapid inpatient intensification. If initiation or addition of antihypertensive is required during admission, the pharmacokinetics of each agent should be carefully considered. Refer to Table 1.

Table 1.

Pharmacokinetics of common oral antihypertensive medications ^a .

Drug class	Initial antihypertensive response	Time to peak (hours)	Duration (hours)
Angiotensin Receptor Blockers (ARB)
Irbesartan	2 h	1.5–2	24
Losartan/carboxylic acid metabolite	Within a week	1–2	24
Telmisartan	<3 h	0.5–1	>24
Valsartan	2 h	0.7–4	24
Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Enalapril/enalaprilat metabolite	1–4 h	1–4.8	12–24
Lisinopril	1 h	Within 7	24
Perindopril/perindoprilat	1.5 h	1–7	24
Dihydropyridines calcium channel blockers
Amlodipine	-	6–12	>24
Nifedipine LA b	-	Plateau at 6 - 12	24
Thiazide/Thiazide-like diuretics
Hydrochlorothiazide	3–4 days	1.5–2.5	6–12
Indapamide SR c	-	12	-
Potassium sparing diuretics
Spironolactone	2–4 h	1–3	16–24
Beta-blockers
Atenolol	3 h	2–4	24
Carvedilol	1 h	1–1.5	24
Labetalol	2–4 h	1–2	8–12
Alpha-1 blockers
Prazosin	Within 2 weeks	0.5–3	7–10
Terazosin	15 min	0.5–1.75	24
Direct vasodilators
Hydralazine	1 h	1–2	3–8

^aInformation obtained from Micromedex® (electronic version). Available at: https://www.micromedexsolutions.com/. Accessed on 24 November 2025. Note that this list is not exhaustive.

^bInformation obtained from Bayer Pharma AG. Adalat® LA. Available at: https://www.bayer.com/sites/default/files/adalat-la-smpc-jul-2016.pdf. Accessed on 25 November 2025.

^cInformation obtained from Servier Laboratories Limited. Natrilix SR 1.5 mg Tablets. Available at: https://www.medicines.org.uk/emc/product/1152/smpc/print. Accessed on 25 November 2025.

It is important to note that many commonly used antihypertensives have delayed onset of action, achieve peak concentrations several hours after dosing and have prolonged durations of action. Administering multiple long-acting oral agents in quick succession can produce an exaggerated fall in BP hours later as their delayed effects accumulate, leading to hypotension and organ hypoperfusion, as illustrated by the case above. If an oral antihypertensive is administered, sufficient time should be allowed for the effect to manifest before reassessment.

Conclusions

Severe asymptomatic hypertension is best managed with careful evaluation, identification of contributors, observation, and prudent adjustment of the antihypertensive regimen. Rapid inpatient intensification, especially stacking long-acting oral agents, should be avoided. In asymptomatic patients, this perceived urgency is often experienced more by clinicians than by patients, driven by terminology rather than evidence. The recent American Heart Association/American College of Cardiology 2025 Hypertension Guideline replaces the term “hypertensive urgency” with “severe hypertension”. ¹ We urge all practitioners to adopt this terminology, which conveys less of a false sense of urgency and better reflects the evidence. We also recommend targeted education for healthcare professionals to recalibrate mindset, align practice with the evidence and prevent unnecessary interventions.